Federal Register / Vol. 83, No. 121 / Friday, June 22, 2018 / Notices 29127 

Enhancement Award; 93.936, NIH Acquired 

Immunodeficiency Syndrome Research Loan 

Repayment Program; 93.187, Undergraduate 

Scholarship Program for Individuals from 

Disadvantaged Backgrounds, National 

Institutes of Health, HHS) 

Dated: June 19, 2018. 

Natasha M. Copeland, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2018–13419 Filed 6–21–18; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Prospective Grant of an Exclusive 

Patent License: Methods of Modulating 

Erythropoiesis With Arginine 

Vasopressin Receptor 1B Molecules 

AGENCY: National Institutes of Health, 

HHS. 

ACTION: Notice. 

SUMMARY: The National Institute of 

Dental and Craniofacial Research, an 

institute of the National Institutes of 

Health, Department of Health and 

Human Services, is contemplating the 

grant of an Exclusive Patent License to 

practice the inventions embodied in the 

Patent Applications listed in the 

Supplementary Information section of 

this notice to ERYTHRYx Therapeutics, 

located in Los Angeles, California. 

DATES: Only written comments and/or 

applications for a license which are 

received by the Office of Technology 

Transfer and Innovation Access, 

National Institute of Dental and 

Craniofacial Research on or before July 

9, 2018 will be considered. 

ADDRESSES: Requests for copies of the 

patent application, inquiries, and 

comments relating to the contemplated 

an Exclusive Patent License should be 

directed to: Yun Mei, Technology 

Transfer and Patent Specialist, Office of 

Technology Transfer and Innovation 

Access, National Institute of Dental and 

Craniofacial Research, National 

Institutes of Health, BLDG 1 DEM, 

RM667, 6701 Democracy Blvd., 

Bethesda, MD 20817; Telephone: (301) 

827–4639; Facsimile: (301) 496–1005; 

Email: yun.mei@nih.gov. 

SUPPLEMENTARY INFORMATION: 

Intellectual Property 

1. U.S. Provisional Patent Application 

No. 61/885,258, filed October 1, 2013 

and entitled ‘‘Methods of Modulating 

Erythropoiesis with Arginine 

Vasopressin Receptor 1B Molecules’’ 

(HHS Reference No. E–619–2013–0–US– 

01); 

2. PCT Application No. PCT/US2014/ 

058613, filed October 1, 2014 and 

entitled ‘‘Methods of Modulating 

Erythropoiesis with Arginine 

Vasopressin Receptor 1B Molecules’’ 

(HHS Reference No. E–619–2013–0– 

PCT–02); 

3. U.S. Patent Application No. 15/ 

022,531, filed March 16, 2016 and 

entitled ‘‘Methods of Modulating 

Erythropoiesis with Arginine 

Vasopressin Receptor 1B Molecules’’ 

(HHS Reference No. E–619–2013–0–US– 

03); 

The patent rights in these inventions 

have been assigned and/or exclusively 

licensed to the government of the 

United States of America. 

The prospective exclusive license 

territory may be the United States and 

the field of use may be limited to ‘‘Use 

of arginine vasopressin receptor 1B 

agonists to treat anemia caused by (i) 

chronic renal failure on dialysis, (ii) 

receiving myelosuppressive 

chemotherapy, or (iii) lacking 

antidiuretic hormone.’’ 

The subject technology is a method of 

using arginine vasopressin receptor 1B 

(AVPR1B) agonists to increase the 

number of red blood cells to treat 

anemia. The inventors discovered that 

hematopoietic stem cells express 

AVPR1B receptor, and these receptors 

play a key role in promoting 

hematopoietic stem and progenitor cell 

proliferation. The number of red blood 

cells and their precursors significantly 

increased on day 2 following 

vasopressin administration, an onset 

time much faster than erythropoietin 

(EPO), which is commonly used to 

stimulate red blood cell production for 

anemia treatment. EPO takes about a 

week to manifest its clinical effects. The 

AVPR1B agonists can be used to 

jumpstart the hematopoietic system and 

erythropoietin can be used to sustain 

the effect. 

The subject technology is a 

repurposing of an existing drug, 

vasopressin, an AVPR1B agonist, also 

called antidiuretic hormone. It is a nineamino acid peptide secreted from the 

posterior pituitary and used to treat 

patients with central diabetes insipidus, 

an uncommon disorder that causes an 

imbalance of water in the body. This 

imbalance leads to excretion of large 

amount of urine (polyuria) and intense 

thirst even after drinking fluids 

(polydipsia). 

This notice is made in accordance 

with 35 U.S.C. 209 and 37 CFR part 404. 

The prospective exclusive license will 

be royalty bearing, and the prospective 

exclusive license may be granted unless 

within fifteen (15) days from the date of 

this published notice, the National 

Institute of Dental and Craniofacial 

Research receives written evidence and 

argument that establishes that the grant 

of the license would not be consistent 

with the requirements of 35 U.S.C. 209 

and 37 CFR part 404. 

In response to this Notice, the public 

may file comments or objections. 

Comments and objections, other than 

those in the form of a license 

application, will not be treated 

confidentially, and may be made 

publicly available. 

License applications submitted in 

response to this Notice will be 

presumed to contain business 

confidential information and any release 

of information in these license 

applications will be made only as 

required and upon a request under the 

Freedom of Information Act, 5 U.S.C. 

552. 

Dated: June 19, 2018. 

David W. Bradley, 

Director, Office of Technology Transfer and 

Innovation Access, National Institute of 

Dental and Craniofacial Research, National 

Institutes of Health. 

[FR Doc. 2018–13443 Filed 6–21–18; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

Government-Owned Inventions; 

Availability for Licensing 

AGENCY: National Institutes of Health, 

HHS. 

ACTION: Notice. 

SUMMARY: The invention listed below is 

owned by an agency of the U.S. 

Government and is available for 

licensing to achieve expeditious 

commercialization of results of 

federally-funded research and 

development. Foreign patent 

applications are filed on selected 

inventions to extend market coverage 

for companies and may also be available 

for licensing. 

FOR FURTHER INFORMATION CONTACT: Dr. 

Barry Buchbinder, 240–627–3678; 

barry.buchbinder@nih.gov. Licensing 

information and copies of the U.S. 

patent application listed below may be 

obtained by communicating with the 

indicated licensing contact at the 

Technology Transfer and Intellectual 

Property Office, National Institute of 

Allergy and Infectious Diseases, 5601 

Fishers Lane, Rockville, MD 20852; tel. 

301–496–2644. A signed Confidential 


daltland on DSKBBV9HB2PROD with NOTICES
29128 Federal Register / Vol. 83, No. 121 / Friday, June 22, 2018 / Notices 

Disclosure Agreement will be required 

to receive copies of unpublished patent 

applications. 

SUPPLEMENTARY INFORMATION: 

Technology description follows. 

Recombinant HIV-1 Envelope Protein 

for Vaccine Use 

Description of Technology 

In pursuit of an effective vaccine to 

end the global HIV-1/AIDS pandemic, 

researchers at the Vaccine Research 

Center (‘‘VRC’’) continue to study the 

structure of HIV-1. Recently, these 

researchers have determined the threedimensional structure of the HIV-1 

Envelope trimeric ectodomain (‘‘Env’’), 

comprised of three gp120 and three 

gp41 subunits, in its prefusion, mature, 

closed conformation. 

The researchers hypothesize that 

immunization with the prefusion, 

closed HIV-1 Env protein will elicit a 

neutralizing immune response. The VRC 

researchers engineered a portion of the 

HIV-1 Env trimer to stabilize it in this 

closed conformation for use as an 

immunogen. 

This technology is available for 

licensing for commercial development 

in accordance with 35 U.S.C. 209 and 37 

CFR part 404, as well as for further 

development and evaluation under a 

research collaboration. 

Potential Commercial Applications 

• Vaccine for prevention of HIV-1 

infection. 

• Therapeutic vaccine for treatment 

of HIV-1 infection. 

Competitive Advantages 

• Currently, no licensed HIV-1 

vaccine exists. 

Development Stage 

• In vitro studies characterizing the 

immunogen and its interaction with HIV 

antibodies. 

• In vivo results including 

immunogenicity in rabbits and guinea 

pigs, neutralizing activity of resulting 

serum. 

Inventors: Peter D. Kwong (NIAID), 

Ivelin S. Georgiev (NIAID), Michael 

Gordon Joyce (NIAID), Marie L. Pancera 

(NIAID), Tongqing Zhou (NIAID), 

Priyamvada Acharya (NIAID), Jason J. 

Gorman (NIAID), Yongping Yang 

(NIAID), Aliaksandr A. Druz (NIAID), 

Guillaume Stewart-Jones (NIAID), Rita 

Chen (NIAID), Gwo-Yu Chuang (NIAID), 

Ulrich Baxa (NIAID), John R. Mascola 

(NIAID), Rebecca M. Lynch (NIAID), 

Baoshan Zhang (NIAID), Cheng Cheng 

(NIAID). 

Publications: Pancera M., et al. 

Structure and immune recognition of 

trimeric pre-fusion HIV-1 Env. Nature. 

2014 Oct 23; 514(7523):455–61. [PMID: 

25296255]. 

Intellectual Property: HHS Reference 

Number E–178–2014 includes U.S. 

Provisional Patent Application No. 62/ 

046,059 filed September 4, 2014; U.S. 

Provisional Patent Application No. 62/ 

136,480 filed March 21, 2015; PCT 

Application No. PCT/US2015/048729 

filed September 4, 2015; U.S. Patent 

Application No. 15/508,885 filed March 

3, 2017; and EPO Patent Application 

No. 15766697.5 filed March 29, 2017. 

Licensing Contact: Dr. Barry 

Buchbinder, 240–627–3674; 

barry.buchbinder@nih.gov. 

Collaborative Research Opportunity: 

The National Institute of Allergy and 

Infectious Diseases is seeking statements 

of capability or interest from parties 

interested in collaborative research to 

further develop, evaluate, or 

commercialize HIV-1 immunogens for 

treating or preventing HIV-1 infection. 

For collaboration opportunities, please 

contact Dr. Barry Buchbinder, 240–627– 

3674; barry.buchbinder@nih.gov. 

Dated: June 14, 2018. 

Suzanne M. Frisbie, 

Deputy Director, Technology Transfer and 

Intellectual Property Office, National Institute 

of Allergy and Infectious Diseases. 

[FR Doc. 2018–13416 Filed 6–21–18; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Eye Institute; Notice of Closed 

Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The grant applications and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the grant 

applications, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Eye Institute 

Special Emphasis Panel; NEI Cooperative 

Agreement (UG1) and Clinical Trial Planning 

Grant (R34) Applications. 

Date: July 13, 2018. 

Time: 1:00 p.m. to 4:00 p.m. 

Agenda: To review and evaluate 

cooperative agreement applications. 

Place: National Institutes of Health, 5635 

Fishers Lane, Bethesda, MD 20892 (Virtual 

Meeting). 

Contact Person: Anne E. Schaffner, Ph.D., 

Chief, Scientific Review Branch, Division of 

Extramural Research, National Eye Institute, 

5635 Fishers Lane, Suite 1300, MSC 9300, 

Bethesda, MD 20892–9300, (301) 451–2020, 

aes@nei.nih.gov. 

Name of Committee: National Eye Institute 

Special Emphasis Panel; NEI Research 

Project Grant Applications (R01). 

Date: July 25, 2018. 

Time: 12:00 p.m. to 2:00 p.m. 

Agenda: To review and evaluate grant 

applications. 

Place: National Institutes of Health 5635 

Fishers Lane, Bethesda, MD 20892 

(Telephone Conference Call). 

Contact Person: Brian Hoshaw, Ph.D., 

Scientific Review Officer National Eye 

Institute National Institutes of Health, 

Division of Extramural Research 5635 Fishers 

Lane, Suite 1300, Rockville, MD 20892, 301– 

451–2020, hoshawb@mail.nih.gov. 

(Catalogue of Federal Domestic Assistance 

Program Nos. 93.867, Vision Research, 

National Institutes of Health, HHS) 

Dated: June 19, 2018. 

Natasha M. Copeland, 

Program Analyst, Office of Federal Advisory 

Committee Policy. 

[FR Doc. 2018–13413 Filed 6–21–18; 8:45 am] 

BILLING CODE 4140–01–P 

DEPARTMENT OF HEALTH AND 

HUMAN SERVICES 

National Institutes of Health 

National Institute on Drug Abuse; 

Notice of Closed Meetings 

Pursuant to section 10(d) of the 

Federal Advisory Committee Act, as 

amended, notice is hereby given of the 

following meetings. 

The meetings will be closed to the 

public in accordance with the 

provisions set forth in sections 

552b(c)(4) and 552b(c)(6), Title 5 U.S.C., 

as amended. The contract proposals and 

the discussions could disclose 

confidential trade secrets or commercial 

property such as patentable material, 

and personal information concerning 

individuals associated with the contract 

proposals, the disclosure of which 

would constitute a clearly unwarranted 

invasion of personal privacy. 

Name of Committee: National Institute on 

Drug Abuse Special Emphasis Panel; 

Receptor Profiling and Predictive Toxicology 

(8937). 

Date: July 19, 2018. 

Time: 10:00 a.m. to 12:30 p.m. 

Agenda: To review and evaluate contract 

proposals. 

Place: National Institutes of Health, 

Neuroscience Center, 6001 Executive 

Boulevard, Rockville, MD 20852 (Telephone 

Conference Call). 


daltland on DSKBBV9HB2PROD with NOTICES